Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Osiris receives $224.7M defense contract

The U.S. Department of Defense awarded Osiris (NASDAQ:OSIR) a $224.7 million contract to develop and stockpile Prochymal for the repair of

Read the full 214 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE